However, sorafenib-induced phosphorylation of Akt and p65 was significantly inhibited in combined treatment with HsA (Figure S5c,d), suggesting HsA may have the potential for inhibiting the viability of HCC cells that have already acquired resistance to sorafenib. The gene discussed is ALB; the disease is hepatocellular carcinoma.